Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gut metabolomics profiling of non-small cell lung cancer (NSCLC) patients under immunotherapy treatment
Andrea Botticelli, Pamela Vernocchi, Federico Marini, et al.
Journal of Translational Medicine (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 159

Showing 1-25 of 159 citing articles:

Generation of systemic antitumour immunity via the in situ modulation of the gut microbiome by an orally administered inulin gel
Kai Han, Jutaek Nam, Jin Xu, et al.
Nature Biomedical Engineering (2021) Vol. 5, Iss. 11, pp. 1377-1388
Open Access | Times Cited: 170
Gut microbiota-derived short-chain fatty acids and colorectal cancer: Ready for clinical translation?
Huiqin Hou, Danfeng Chen, Kexin Zhang, et al.
Cancer Letters (2021) Vol. 526, pp. 225-235
Closed Access | Times Cited: 152
Targeting the gut microbiota for cancer therapy
Miriam R. Fernandes, Poonam Aggarwal, Raquel Costa, et al.
Nature reviews. Cancer (2022) Vol. 22, Iss. 12, pp. 703-722
Closed Access | Times Cited: 147
Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
Despoina Chrysostomou, Lauren A. Roberts, Julian R. Marchesi, et al.
Gastroenterology (2022) Vol. 164, Iss. 2, pp. 198-213
Open Access | Times Cited: 127
Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment
Michelle Hanus, Daniela Parada-Venegas, Glauben Landskron, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 122
Intestinal Microbiota-Derived Short Chain Fatty Acids in Host Health and Disease
Jing Cong, Ping Zhou, Ruiyan Zhang
Nutrients (2022) Vol. 14, Iss. 9, pp. 1977-1977
Open Access | Times Cited: 121
Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites
Claudia Grajeda‐Iglesias, Sylvère Durand, Romain Daillère, et al.
Aging (2021) Vol. 13, Iss. 5, pp. 6375-6405
Open Access | Times Cited: 116
Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer
Eiko Hayase, Robert R. Jenq
Genome Medicine (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 108
To metabolomics and beyond: a technological portfolio to investigate cancer metabolism
Federica Danzi, Raffaella Pacchiana, Andrea Mafficini, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 104
A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Qiqing Yang, Bin Wang, Qinghui Zheng, et al.
Advanced Science (2023) Vol. 10, Iss. 15
Open Access | Times Cited: 89
Gut microbiota: A new insight into lung diseases
Peijun Ma, Mengmeng Wang, Yun Wang
Biomedicine & Pharmacotherapy (2022) Vol. 155, pp. 113810-113810
Open Access | Times Cited: 79
Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities
Ghanyah Al-Qadami, Kate R. Secombe, Courtney B. Subramaniam, et al.
Microorganisms (2022) Vol. 10, Iss. 10, pp. 2048-2048
Open Access | Times Cited: 77
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Rebecca Simpson, Erin R. Shanahan, Richard A. Scolyer, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 697-715
Closed Access | Times Cited: 53
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target
Mengwei Zhang, Jinkai Liu, Qiang Xia
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 44
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy
Xing Kang, Harry Cheuk-Hay Lau, Jun Yu
Cell Reports Medicine (2024) Vol. 5, Iss. 4, pp. 101478-101478
Open Access | Times Cited: 36
Fatty acid metabolism of immune cells: a new target of tumour immunotherapy
Sheng Zhang, Kebing Lv, Zhen Yu Liu, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 34
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies
Jindong Xie, Manqing Liu, Xinpei Deng, et al.
iMeta (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 31
Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review)
Jinzhe Sun, Shiqian Chen, Dan Zang, et al.
International Journal of Oncology (2024) Vol. 64, Iss. 4
Open Access | Times Cited: 30
Network Analysis of Gut Microbiome and Metabolome to Discover Microbiota-Linked Biomarkers in Patients Affected by Non-Small Cell Lung Cancer
Pamela Vernocchi, Tommaso Gili, Federica Conte, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8730-8730
Open Access | Times Cited: 110
Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
Andrea Botticelli, Alessio Cirillo, Lidia Strigari, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 81
Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer
Veronica Ghini, Letizia Laera, Beatrice Fantechi, et al.
Cancers (2020) Vol. 12, Iss. 12, pp. 3574-3574
Open Access | Times Cited: 72
Metabolomics, metabolic flux analysis and cancer pharmacology
Lingfan Liang, Fei Sun, Hongbo Wang, et al.
Pharmacology & Therapeutics (2021) Vol. 224, pp. 107827-107827
Closed Access | Times Cited: 65
The heightened importance of the microbiome in cancer immunotherapy
C Villemin, Anne Six, Bridget A. Neville, et al.
Trends in Immunology (2022) Vol. 44, Iss. 1, pp. 44-59
Open Access | Times Cited: 49
Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts
Xiaowen Huang, Muni Hu, Tiantian Sun, et al.
Cell Host & Microbe (2023) Vol. 31, Iss. 11, pp. 1930-1943.e4
Open Access | Times Cited: 37
The cancer-immune dialogue in the context of stress
Yuting Ma, Guido Kroemer
Nature reviews. Immunology (2023) Vol. 24, Iss. 4, pp. 264-281
Closed Access | Times Cited: 32
Page 1 - Next Page

Scroll to top